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Tuberculous meningitis (TBM) is a prevalent form of central nervous system tuberculosis (CNS-TB) and 
the most severe common form of bacterial meningitis in infants and children below the age of 13 years, 
especially in the Western Cape Province of South Africa. Research to identify markers for timely and accurate 
diagnosis and treatment outcomes remains high on the agenda for TBM, in respect of which the field of 
metabolomics is as yet largely unexploited. However, the national Department of Science and Technology 
(DST) recently established several biotechnology platforms at South African institutions, including one for 
metabolomics hosted at North-West University. We introduce this national platform for nuclear magnetic 
resonance (NMR) metabolomics by providing an overview of work on TBM. We focus on selected 
collaborative multidisciplinary approaches to this disease and conclude with the outcomes of an untargeted 
NMR metabolomics study of cerebrospinal fluid from TBM patients. This study enabled the formulation of 
a conceptual shuttle representing the unique metabolic plasticity of CNS metabolism towards the energy 
requirements for the microglia-driven neuroinflammatory responses, of which TBM is one example. From 
insights generated by this explorative NMR metabolomics investigation, we propose directions for future 
in-depth research strategies to address this devastating disease. In our view, the timely initiative of the 
DST, the operational expertise in metabolomics now available and the potential for involving national and 
international networks in this field of research offers remarkable opportunities for the future of metabolomics 
in South Africa and for an ever greater understanding of disease mechanisms.
Introduction
Metabolomics has become an established scientific field. It provides analytical, chemical and physiological 
insights into naturally occurring, low-molecular-weight organic metabolites within organisms, cells, tissues and 
biofluids, and helps to promote understanding of metabolite interactions.1 Explorative metabolomics investigations 
produce metabolite profiles and rely on the scientific method of induction to generate hypotheses in order to 
identify metabolites that may be indicators or biomarkers of disease or used as monitors of therapeutic responses.2 
Tuberculosis (TB), in its variety of manifestations – such as pulmonary and pleural TB, as well as TB within the 
central nervous system (CNS-TB), with tuberculous meningitis (TBM) as one of its most dangerous forms – is 
high on the list for such applications. Although still limited in number, metabolomic technologies have been applied 
successfully to diseases of the CNS. The composition of cerebrospinal fluid (CSF), which is partially derived from 
interstitial fluid in the CNS, is anticipated to reflect the normal and pathological biochemical processes of the brain. 
In the present review, we start by addressing the pathophysiology and severity of TBM and follow with a discussion 
on the application of metabolomics in enriching our understanding of this infectious disease. Research on TB, in 
its broadest sense, has a long-standing history in South Africa, emanating from several leading research units 
and centres, and directed and staffed by world-renowned scholars. Their contributions warrant a review alone 
and are not covered here; our main focus is on TBM, the latest pioneering investigations using nuclear magnetic 
resonance (NMR) metabolomics, and perspectives on methodological approaches that further exploratory insights 
and hypotheses formulated through metabolomics studies.
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. Although TB commonly presents as a 
pulmonary disease, systemic spread of the tubercule bacilli can lead to extrapulmonary forms of TB (EPTB), 
present in up to 20% of reported TB cases,3 and particularly common in young children and immunocompromised 
individuals4. CNS-TB represents up to an estimated 10% of all EPTB (and 1% of total TB) cases.3,5 According to 
the World Health Organization Global TB Report for 2014, there were 312 380 clinically defined new cases of TB 
in South Africa alone; of these, 37 709 (12%) were EPTB, which included an estimated 3771 cases of CNS-TB. 
Among the various manifestations of TB, TBM is not only the most prevalent form of CNS-TB but is also the 
most severe complication of TB and the most common form of bacterial meningitis in children below the age of 
13 years6, especially in the Western Cape Province of South Africa7,8.
Recent reviews have covered various aspects of childhood TBM.9-11 The general consensus emerging from these 
reports is that: (1) progress in understanding, prevention and treatment of TBM remains inadequate; (2) childhood 
deaths and disability as a result of TBM constitute a major societal burden; (3) although preliminary results obtained 
with the Bacillus Calmette–Guérin (BCG) vaccine seem to be promising for protection against TB, future trials of 
candidate vaccines are still needed; and (4) novel research to improve timely and accurate diagnosis and treatment 
outcomes remains high on the agenda. TBM is a disease that is largely unexploited by metabolomics technology, 
which predominantly makes use of hyphenated mass spectroscopy (MS) and NMR spectroscopy – the latter being 
the focus of this overview.
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Pathogenesis and severity of TBM
Tuberculosis is spread via an aerosol route from persons who have active 
disease. Most people infected with M. tuberculosis have latent disease 
and are asymptomatic. However, a small proportion of individuals go on 
to develop active TB – with some developing systemic TB, such as TBM 
– and have significant morbidity and mortality, even though effective 
treatment is available.
In the late 19th century, it was thought that TBM resulted from haema-
togenous spread to the meninges, as a result of the frequent finding that 
TBM and miliary TB were occurring in the same patients.12 In 1933 Rich 
and McCordock13 published their report that, in the majority of post-
mortems, a single caseous focus (Rich’s focus) could be found, from 
which, when ruptured, bacilli could spread to the subarachnoid space. 
It was thought that this single lesion was almost always older than all 
the lesions found in concurrently occurring miliary TB, which set the 
paradigm for understanding the pathogenesis of TBM. However, this 
model did not fully explain the frequency of miliary TB and TBM occurring 
simultaneously14, nor the mechanism whereby M. tuberculosis spreads 
from the lungs to the meninges and crosses the blood–brain barrier15. 
Animal models have been developed in order to understand better the 
pathogenesis of CNS-TB but findings are frustrated by the poor human 
clinical–pathological correlation.15 Magnetic resonance imaging has 
detected numerous concurrent leptomeningeal granulomas in children 
with miliary TB, further challenging Rich’s pathogenic model.15,16 It is 
likely that early haematogenous spread to the brain occurs before a T-cell 
mediated immune response is activated. This mechanism could explain 
the vulnerability to TBM when T-cell mediated immunity is sub-optimal 
in persons infected with the human immunodeficiency virus (HIV)9 
and in persons on long-term glucocorticoid therapy17. The protective 
role of lymphocytes is essential, with the contribution of CD4+ and 
CD8+ T-cells, along with macrophages in isolating and engulfing 
M. tuberculosis; together, these eventually lead to granuloma formation. 
We, and others, have shown that many of the signs, symptoms and 
sequelae of TBM result from an immunologically directed inflammatory 
response to the infection.18,19
Greater understanding of the entry of M. tuberculosis into the CNS 
and the immunological mechanisms allowing survival of the bacilli is 
crucial for improving prevention and treatment. Fluctuation in cytokine 
levels affecting immunological function in patients with TBM can directly 
influence the duration of the disease and its severity.18 In particular, the 
balance between pro- and anti-inflammatory cytokines may be crucial 
to TBM disease progression19; this relationship is reflected by the 
upregulation in CSF of pro- and anti-inflammatory cytokines in patients 
with TBM compared to patients with other forms of meningitis.20,21 The 
early clinical presentation of TBM is often non-specific, with symptoms 
such as cough, loss of weight, fever, vomiting and malaise. As the disease 
progresses, meningism, focal neurological signs, and a depressed level 
of consciousness can occur. The timing of initiation of treatment is the 
most critical factor affecting morbidity, mortality, and healthcare costs, 
which emphasises the importance of early diagnosis of TBM.22 Through 
a large retrospective study of 554 children with TBM, we established that 
14% presented with visual impairment, 16% with hearing loss, 44% with 
motor deficits and 77% with intellectual impairment; only a small number 
(16%) did not have neurological manifestations of TBM.23 
Accurate prediction of outcome in childhood TBM is difficult owing to 
the diversity of underlying pathological mechanisms and variation in host 
immunological response. Multidrug-resistant (MDR) TBM in children 
has a poor clinical outcome and is associated with increased mortality.24 
In-patient mortality rates do not differ between HIV-infected and non-
HIV-infected children with TBM; however, mortality after hospital 
discharge is greater in HIV-infected children with TBM because of HIV-
related illnesses.25 Even though outcome prediction is problematic, the 
clinical stage of disease at the time of starting treatment is predictive 
of prognosis.11 Children with Stage I TBM disease are likely to lead a 
normal life without neurological complications, whereas those with 
Stage III disease have a high risk of mortality.11 Of all the TBM staging 
systems, the refined Medical Research Council scale has been shown to 
have the highest predictive value.26,27 The criteria that define each stage 
are as follows: Stage I – Glasgow Coma Scale (GCS) of 15 and no focal 
neurology; Stage IIa – GCS of 15 plus focal neurology; Stage IIb – GCS of 
11–14 with focal neurology; and Stage III – GCS <11.26,27 The importance 
of early diagnosis corresponding to an early TBM stage is emphasised 
by the significantly increased risk, as the disease progresses, of severe 
motor deficit and degree of intellectual disability in children classified as 
Stage IIb compared to those classified as Stage IIa.27 Stage III disease 
carries a 73% risk of the patient developing spastic quadriparesis and a 
mean developmental quotient of 44.27 Besides the prediction of disease 
outcome according to TBM stage, convulsions, headache, motor deficit, 
brainstem dysfunction and cerebral infarctions on neuroimaging were 
independently associated with poor clinical consequences of TBM in 
multivariate analysis.23
CSF diagnostic indicators of TBM
Cerebrospinal fluid findings are integral to the diagnosis of TBM. Typical CSF 
findings consist of leukocytosis with lymphocyte predo minance, elevated 
protein and abnormally decreased CSF glucose (hypoglycorrhachia).28 
Hypoglycorrhachia is indicated by either decreased CSF to plasma glucose 
ratio or reduced CSF glucose, and is unaffected by HIV co-infection.29 A 
uniform research case definition for TBM identified CSF criteria to aid in 
the diagnosis of TBM, including a CSF to serum glucose ratio of less than 
0.5 or an absolute CSF glucose concentration of less than 2.2 mmol/L and 
elevated CSF protein of greater than 1 g/L.
There is potential for the use of CSF lactate in children with TBM, as 
CSF lactate has been shown to differentiate between bacterial and 
aseptic meningitis.30 CSF lactate levels, unaffected by serum lactate 
concentration, were significantly higher in adult TBM patients who 
subsequently died than in those who survived, reflecting the severity of 
cerebral hypoxia and therefore the overall prognosis.31 The diagnostic 
utility of CSF indicators considered in TBM has, however, rarely been 
described. Studies evaluating CSF IGRA (interferon-gamma release 
assay) showed good sensitivity and specificity,32 but the low CSF 
volumes in children are a limitation when sufficient cells are required 
to perform IGRA (typically 5–10 mL CSF is required).11 A study of the 
host immune response to M. tuberculosis showed the potential value of 
CSF interleukin-13, vascular endothelial growth factor and cathelicidin 
LL-37 as indicators when differentiating TBM from other forms of 
meningitis.18 Understanding the host immune response is key to a better 
understanding of the pathophysiology, the clinical presentation of TBM 
and the treatment of the disease. Novel indicators from CSF, including 
those from validated metabolomics studies, have the potential to be 
extremely useful as diagnostic tools in clinical practice.
NMR metabolomics methodology and 
applications
Metabolomics involves the simultaneous and comprehensive analysis of 
the measured responses of various biologically relevant small molecules, 
collectively referred to as the metabolome. The metabolome in turn is 
defined as the quantitative and qualitative collection of all low molecular 
weight molecules (metabolites, the end products of gene expression) 
of interest; they are found in concentrations varying in magnitude from 
picomoles to millimoles, they originate from endogenous or exogenous 
sources, and they exhibit a wide range of physico-chemical properties.33 
These small molecules display characteristics which allow metabolomics 
to avoid several challenges associated with genomics and proteomics 
investigations. The great chemical complexity of the metabolome, 
however, means that a single analytical technique is not sufficient to 
provide comprehensive characterisation of all metabolites.33 Among the 
techniques available, NMR spectroscopy provides an attractive alternative 
to MS. Although it is less sensitive than its MS-based counterparts, NMR 
(1) allows for a robust and global look at the metabolome – it detects 
all classes of metabolites – making it non-biased; (2) is highly specific, 
allowing for detection of novel compounds; (3) running costs are markedly 
lower than that of other platforms, although initial set-up is expensive; (4) 
requires minimal sample preparation, and hence (5) does not chemically 
alter nor destroy the sample under investigation. NMR thus provides an 
excellent early or explorative view of the metabolome under investigation.34
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The potential of NMR metabolomics in research on infectious human 
diseases has generated unique and novel insight into the underlying 
pathogenesis of these diseases and has unveiled new metabolic 
markers for disease diagnosis.35 Infectious diseases relevant to Africa 
that have been studied using NMR metabolomics include human African 
trypanosomiasis36, schistosomiasis37, malaria38, Leishmaniasis39, 
pneumonia40, and HIV41, as well as TB and TBM (discussed below).
NMR metabolomics of TB and TBM
The potential of metabolomics has been well documented, specifically 
with regard to TB.42 Its value is in the ability to (1) address simultaneously 
a wide array of metabolites from various different biochemical pathways; 
(2) detect and isolate patterns of disturbance for additional, targeted 
investigations; and (3) generate hypotheses to be tested. Godreuil 
et al.43 believe that the new quantitative and bioinformatics approaches 
to the study of the interaction between M. tuberculosis and the infected 
host, and how this interaction influences the infection process, are of 
particular importance, as it is fully accepted in the scientific description 
of infectious diseases that the outcome of transmission, infection and 
disease is dependent on the intrinsic characteristics of both the microbes 
and the host.
It is expected that at different stages of the M. tuberculosis life cycle – for 
example, dormancy, latent infection and active disease – there will be a 
different array of host- and M. tuberculosis-derived metabolites.42 These 
metabolic profiles can best be measured globally via NMR metabolomics 
(Table 1), which has been used successfully to provide insight into 
the metabolic changes in host response. In a pioneering NMR-based 
metabolomics pilot study of the CSF of patients with bacterial meningitis, 
Coen et al.47 detected: (1) elevated lactate and severe glucose depletion; 
(2) impairment of the citric acid cycle caused by reduced production 
of acetyl CoA, resulting in accumulation of pyruvate and generation 
of amino acids via transamination; (3) elevated CSF concentrations of 
pyruvate and amino acids – particularly alanine, isoleucine and leucine; 
and (4) the presence of ketone bodies – 3-hydroxybutyrate, acetoacetate 
and acetone – indicating compensatory response to glucose depletion 
and reduced ATP levels. Notably, the role of amino acid perturbation 
in meningitis is further supported by other studies.48 The metabolite 
profile described by Coen et al.47 for bacterial meningitis corresponds to 
recent MS-based results from our research centre on CSF from a TBM 
patient49 and to sputum from patients with pulmonary TB50. The pilot 
study of Coen et al.47 thus highlights the potential of NMR metabolomics 
in providing a global and unbiased view of metabolic or neurological 
perturbations in infectious diseases, particularly meningitis.
A study by Zhou et al.45 unambiguously identified 35 metabolites in 
sera of TB patients, of which 17 were altered. The majority of altered 
endogenous metabolites in the serum of TB patients were energy related 
– citric acid cycle intermediates, products of glycolysis, amino acids 
and indicators of enhanced lipid degradation – which is consistent with 
other studies. The metabolic processes found to be most significantly 
altered in TB patients were protein biosynthesis, followed by alanine 
metabolism, phenylalanine and tyrosine metabolism, and ammonia 
recycling. Zhou et al.45 go on to state that increased glycolytic products 
could be an index of tissue hypoxia and extent of necrosis as the infection 
progresses, that enhanced lipid degradation can be correlated with 
caseation of host TB granulomas, and that increased formate reflects an 
increased requirement for nucleotide biosynthesis, all of which indicates 
active host inflammatory cell division. A follow-up study by Zhou et al.46 
highlighted the specificity of the metabolite profile of TB patients, 
compared to similar diseases such as representative metabolism-related 
diseases (diabetes mellitus), wasting diseases (malignancy), and lung 
inflammatory diseases (CAP). Consistent with their previous study, they 
found in the plasma: increased levels of lactate, pyruvate, lipids and 
ketone bodies, and decreased levels of glucose, glutamate, glutamine, 
glycerophosphocholine, very low-density lipoproteins and branched-
chain amino acids. While Zhou et al.46 could distinguish TB patients 
statistically, the greatest statistical overlap occurred with the plasma 
profiles of patients with malignancy, indicating that, to some extent, 
the metabolism of TB mimics that of tumour cells. NMR metabolomics 
has also been used to elucidate the mechanism of action of specific 
medication, such as the second-line drug for TB, D-cycloserine, which 
is primarily used to treat MDR-TB.51
Table 1: Insights offered by nuclear magnetic resonance (NMR)-based metabolomics studies specific to tuberculosis (TB) and meningitis
Pathogen Disease
Experimental 
subjects
Insights Reference
Mycobacterium 
tuberculosis
Tuberculosis Adults
Patients with TB were distinguished from healthy controls. Metabolic profile of sera of 
patients with TB indicated significant dysregulation of metabolic pathways, validating 
metabolic profiling of M. tuberculosis-infected murine models (Shin et al.44). Potential 
to develop novel clinical tools for TB diagnosis or therapeutic monitoring and improve 
understanding of disease mechanisms.
Zhou et al.45
M. tuberculosis Tuberculosis Adults
Plasma metabolite profile of patients with TB exhibited specificity when compared 
to representative metabolism-related diseases (diabetes mellitus), wasting diseases 
(malignancy), and lung inflammatory diseases (CAP). The closest comparison to the 
metabolism profile of TB was that of malignant tumours.
Zhou et al.46
Various
Bacterial 
meningitis
Children and 
adults
NMR-based analysis of cerebrospinal fluid (CSF) is feasible and a potentially more 
powerful diagnostic tool than conventional rapid laboratory indicators for distinguishing 
bacterial from viral meningitis (as well as distinguishing between species of bacteria), with 
important implications for early management, reduced empirical use of antibiotics and 
treatment duration.
Coen et al.47
M. tuberculosis
Tuberculous 
meningitis 
(TBM)
Infants and 
children
Differentiation between TBM and non-TBM cases based on 16 NMR-derived CSF 
metabolites – perturbed glucose, highly elevated lactate and several energy-related 
metabolites, signalling components and amino acid shuttles. Postulated the following 
hypothesis: ‘The host’s response to neural infection results in an “astrocyte–microglia 
lactate shuttle” that operates in neuroinflammatory diseases, such as TBM.’
Mason et al.52
Various Meningitis Children
Integration of NMR spectral information with routine clinical features that are incorporated 
into an in-house software system which allows for the rapid differential diagnosis of 
meningitis (bacterial, TB and viral). 
Subramanian et al.53
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We have recently used a gas chromatography–mass spectrometry 
(GC–MS) approach to investigate the analytical repeatability of a CSF 
sample collected from a TBM patient for metabolomics analysis49 in 
order to develop a new method for evaluating repeatability in generating 
metabolomics data. This study clearly indicated the severe disease 
state of the TBM patient from whom the sample was obtained. We 
subsequently embarked on a comprehensive untargeted proton 
magnetic resonance (1H NMR)-based metabolomics analysis on 
lumbar CSF samples from three experimental groups: (1) South African 
infants and children with confirmed TBM; (2) treated, non-meningitis 
South African infants and children as controls; and (3) age-matched 
untreated controls from the Netherlands.52 Our primary focus was on 
identification of metabolites that distinguish between TBM and non-TBM 
cases; a total of 16 NMR-derived CSF metabolites was identified. These 
metabolites did not include cyclopropane, a putative marker for TBM 
defined in 2005.53 The defining two metabolites were the combination 
of perturbed glucose and highly elevated lactate, common to some 
other neurological disorders. Glucose, the primary source for energy 
production, is utilised in a rapid fashion, resulting in a significant 
increase in CSF lactate, both of which reflect a metabolic burst. The 
remaining 14 metabolites of the host’s response to TBM were likewise 
mainly energy-associated indicators. Citrate and pyruvate, along with 
acetate in the form of acetyl-CoA, are key metabolites involved in the 
citric acid cycle as part of energy production. Alanine and the branched-
chain amino acids – valine, leucine and isoleucine – have vital roles 
as shuttling systems transporting metabolites across cell membranes; 
they are also anaplerotic, replenishing citric acid cycle intermediates. 
Myo-inositol acts as an important signalling component necessary for 
immune responses such as microglia activation. The remaining other 
metabolites also have important roles; one such is dimethyl sulfone, 
which is an indicator of response to oxidative stress; another is choline, 
an important precursor to acetylcholine, which in excess is responsible 
for seizures. 
The most conspicuous outcome of the NMR profiling was the high 
concentration of lactate in the TBM patients (7.36 mmol/L) relative to the 
two control groups (1.39 mmol/L and 1.70 mmol/L for the Dutch and 
South African controls, respectively). This observation has some clinical 
significance. It has been established54 that CSF lactate is applicable as 
a marker that can differentiate bacterial meningitis (>6 mmol/L) from 
other forms of meningitis, such as aseptic meningitis (<2 mmol/L). 
Thus, CSF concentrations of lactate, as well as immune biomarkers, are 
typically high before treatment and then decrease rapidly with therapy. 
In this regard a study55 on adults suffering from meningitis indicated 
that death was associated with high initial CSF concentrations of 
lactate and low numbers of white blood cells, in particular neutrophils. 
This outcome underscores the authors’ proposal that CSF lactate is a 
good single indicator of the TBM disease state, making it better than 
conventional markers.
Furthermore, our NMR-profiling results52 provided a basis for hypothesis 
formulation of the pathogenic characteristics of TBM. We speculated 
that the inflammatory responses and metabolic imbalances created in 
the CNS following the initial phases of infection by a pathogen, such as 
M. tuberculosis, should advantage the microglia (the native macrophage 
in the brain) by fulfilling their energy-intensive immune-protective function. 
This speculation was made against the multi-paradigm background of the 
current literature and based on: (1) the shift in energy requirements as a result 
of the neuroinflammatory responses in TBM; (2) the notion that microglia 
play an important role in the neuropathogenesis of TBM; (3) recognition of 
the unique metabolic plasticity of cell–cell communication and regulation 
in CNS metabolism; and (4) the clinical profile on dysfunctional neuron 
activity seen in TBM. From observations and through inductive reasoning56 
on the characteristics of the cell–cell interactions and factor isoforms, 
we advanced the following hypothesis: ‘The host’s response to neural 
infection results in an “astrocyte–microglia lactate shuttle” (AMLS) that 
operates in neuroinflammatory diseases, such as TBM’, represented as a 
conceptual model detailed in the supplementary material of Mason et al.52 A 
simplified representation of the conceptual model is presented in Figure 1. 
Infection with pulmonary derived Mtb through the circulation:
(Highly elevated lactate (7+mmol/L))
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Figure 1: Representation of metabolic pathways of two lactate shuttles within the central nervous system. (1) The astrocyte–neuron lactate shuttle (ANLS; 
green pathway)58 is operative under normal physiological conditions with astrocytes responding to glutamatergic activation by increasing their rate 
of glucose utilisation and release of lactate in the extracellular space, making the lactate available for neurons to sustain their energy demands. 
(2) The hypothetical astrocyte–microglia lactate shuttle (AMLS; red pathway)52 proposed for tuberculous meningitis (TBM), with astrocytes 
responding to signalling from Mycobacterium tuberculosis (Mtb)-infected microglia by increasing glucose mobilisation, leading to increased 
extracellular lactate, reflected in increased cerebrospinal fluid (CSF) lactate levels, available as an additional energy source for reactive oxygen 
species (ROS) production aimed at destroying the invading Mtb.
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Briefly, it is postulated that, in TBM, lactate produced through glycolysis 
in astrocytes partici pates in the activated immune response and is 
directed from the neurons preferentially into microglia, where it enters the 
mitochondrial citric acid cycle, contributing to oxidative phosphorylation 
and hence producing high levels of adenosine triphosphate (ATP) and 
formation of reactive oxygen species (ROS) required for M. tuberculosis 
degradation. ROS, and a multitude of factors produced by the microglia 
to modulate the functions of surrounding immune cells, are toxic to 
neurons. Moreover, the unregulated activation of microglia in response to 
stimulants such as M. tuberculosis propagate neural injury57 and eventual 
apoptotic cell death for the over-activated microglia. By contrast, several 
investigations indicate that astrocytes could release large amounts of 
lactate under conditions of high energy demand by the neurons, leading 
to our hypothesis of an activity-dependent astrocyte–neuron lactate shuttle 
for the supply of energy substrates to neurons.58
From the preceding overview we highlight the following insights that 
have transpired from the NMR metabolomics of TB and TBM.
Advantages of NMR technology for clinical applications
(1) Non-invasive sample collection methods are often essential in 
clinical medicine, for which body fluids such as urine, cord blood and 
serum/plasma are particularly suited, with NMR spectroscopy providing 
a cornerstone for their metabolomics investigations. In addition, NMR 
spectroscopy can work with small sample volumes. 
(2) NMR analyses require a minimum of sample pre-preparation and 
thereby prevent the occurrence of confounding analytical artefacts. 
(3) Metabolomics produces large and complex data sets that cannot 
be interpreted through classic reductionist methods, but require an 
inductive, open-minded approach, aimed at hypothesis generation, 
which is philosophically a useful methodological approach in uncharted 
fields of research. 
(4) Clinically, perturbations in metabolism are often difficult to recognise 
as the phenotypes may show considerable variation; however, NMR 
technology has provided a proven track record through the identification 
of inborn errors of metabolism, often already manifesting in neonates.
(5) The unique advantage of metabolomics technology is that it provides 
a dynamic view of host functional responses in health and disease, 
and offers early and rapid identification of the status and progress of 
a disease.
Cost-effectiveness of NMR technology
High-resolution NMR equipment, such as the instrument installed in 
early 2015 in a collaboration between the Technological Innovation 
Agency (TIA) and North-West University (NWU), is extremely expensive 
and requires highly skilled technical and scientific expertise for its 
operation. However, once an NMR facility has been established, the 
analytical clinical analysis is relatively inexpensive, costing only a few 
rands per sample to run. Moreover, the international trend in the market 
for miniaturisation of NMR instrumentation is well established, and is 
opening up new areas of study in academic and industrial settings with 
clear potential and appeal for future clinical practice.59
Systems insights
Fields that are data rich but hypothesis poor – prime examples are 
systems biology and many areas of medicine and clinical practice – 
are best approached through data-driven, essentially inductive methods. 
Biological systems are inherently complex; they require an inductive 
approach to data generation, data analysis and modelling if we are to 
continue to make strides in our understanding of these phenomena 
in health and disease. The advent of multidisciplinary interaction 
between biologists/clinicians, analytical chemists and informaticists/
biostatisticians in developing complex models has ushered in a new era in 
the mathematics of science, for the first time enabling understanding and 
prediction of large-scale biological systems; the ‘omics’ technologies 
are key in this process by being inductive and exploratory in their very 
essence. Intrinsic to this process remains the iterative relationship 
between the realm of ideas/hypotheses/thoughts (= induction) and that 
of observations/data/information (= deduction), linked in a repetitive 
cyclic way in which one arc is not simply the reverse of the other, but 
has methodological characteristics in its own right. We conclude our 
overview by focusing on this cyclic relationship.
Directives for hypothesis verification
Hypotheses are generalised statements derived from empirical 
evidence and prior knowledge of existing data, and they need to be 
verified or refuted by deductive methods (Figure 2). This activity can 
be represented as a circular process, with inductive reasoning forming 
one half of the iterative cycle of knowledge, and the second half 
(deduction) devoted to the aims of testing hypotheses and furthering 
existing knowledge. This representation highlights the essential nature of 
exploratory metabolomics investigations, and features three approaches 
that could be applied for hypothesis testing: (1) computational models, 
(2) animal models and (3) semi-targeted metabolomics.
Computational modelling
The extreme complexity of intracellular regulatory networks, involving 
genetic circuits, metabolic regulation and signal transduction, hampers 
the ability to analyse these functions quantitatively to achieve a holistic 
understanding of their role in health and disease. Complexity theory has 
thus become established over the last two decades as a novel discipline 
directed to such problems in the humanities and natural sciences, and is 
at present pursued in South Africa at the Centre for Studies in Complexity 
established in 2009 at Stellenbosch University. Modelling, in its various 
forms, demands key competencies in studying complexity. Models are 
used to describe complex systems through computer simulation based 
on quantitative information on many and key variables that characterise 
what is being investigated. An example is the computational model 
we recently developed – using in silico data that capture the unique 
immunological environment of the brain – which allows us to study the 
key mechanisms driving TB-linked granuloma formation in time.60 The 
model was based on a known pulmonary agent-based description of 
TB, representing the molecular signalling networks that affect granuloma 
formation during infection with M. tuberculosis. It focused on the 
formation of granulomas whose structure and function may reflect 
the success or failure of the host to contain infection. We envisage 
that computational model development, based on NMR data, may be 
a fruitful approach to use for understanding the dynamics involved in 
metabolic flux associated with the AMLS hypothesis, thereby permitting 
greater comprehension of the perturbations following M. tuberculosis 
infection of the microglia in the meninges.
Experimentation using animal models
Animal models have contributed significantly to knowledge of TB. 
However, there are certain major differences between humans and 
other animals in their responses to the disease. It is known that mice, 
for example, do not form the granulomas seen in humans and most 
other vertebrates with TB. Such differences caution our interpretations of 
data from animal models as they apply to human diseases. Nonetheless, 
animal models are indispensable to TB research and are well established 
in South African TB research centres.61,62 Until recently, for example, 
no murine model was available for experimental studies on TBM. We 
successfully developed a reproducible in vivo murine model to study the 
inflammatory response in TBM,63 and obtained useful insights despite 
limitations in translating the experimental observations to the human 
manifestation of the disease. Although the route of infection mimics the 
way TBM is acquired naturally, the cytokine profile in the mice does not 
show the clinical characteristics of the human disease. Nonetheless, 
the model has potential for further experimentation on M. tuberculosis 
infection because we observed that bacterial growth of TB in the CNS 
leads to a typical chronic inflammatory response. Such results indicate 
that experimental animal studies hold potential for investigating the 
biological changes in a M. tuberculosis-infected model at the biochemical 
level – an approach that could be expanded through appropriate knock-
out models, as has been shown for cryptococcal meningitis.64
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Semi-targeted metabolomics
The metabolites present in the CSF represent the actual metabolism of 
the CNS and the balance between blood and CSF, rendering CSF analysis 
indispensable in the assessment of neurological disorders. Sampling 
human CSF is, however, an invasive procedure and ethical and safety 
constraints limit the availability of such samples for TBM, especially 
in work with infants and children. Thus, accessing these samples is 
much more difficult than collecting blood or urine. Metabolomics offers 
promising options. The use of MS-based metabolomics of plasma from 
patients suffering from propionic acidemia and methylmalonic acidemia,65 
as well as our GC-MS metabolomics analysis of urine samples from 
patients with respiratory chain deficiencies66 and isovaleric acidemia67, 
have provided proof of concept that semi-targeted metabolomics can 
expand the range of metabolites associated with human disease. These 
studies also indicate the potential of metabolomics for non-invasive 
diagnosis and clinical evaluation of patients with TBM.
Perspective
Metabolomics studies of complex diseases are still in their infancy, 
although the volume of NMR- and MS-based metabolomics publica-
tions in particular is increasing exponentially.2 As it stands, NMR 
metabolomics is not a standalone method of diagnosis nor, by extension, 
of disease management of TB or of TBM, but it undeniably offers insights 
for potentially improving existing knowledge of infectious diseases in 
ways that may complement and benefit current diagnostic and treatment 
methods. Recent results, such as those by Zhou et al.46, strongly indicate 
that NMR metabolomics can contribute to improved understanding of 
disease mechanisms. However, a major gap in work on infectious 
diseases is still the paucity of subsequent validation of clinical studies, 
which is necessary to reap the full rewards of metabolomics technology. 
Ultimately, the optimal outcome, particularly in resource-limited settings, 
is the validation and declaration of simple and clear biomarkers for 
disease diagnosis – which requires appropriate and thorough follow-ups 
on metabolomics studies. 
Fortunately, the great potential of biotechnology was recognised by the 
Department of Science and Technology, which enabled the creation of 
several technological platforms, including the Metabolomics Platform 
supported by the TIA and hosted by NWU on its Potchefstroom 
campus. This platform consists of a wide array of gas and liquid 
chromatography based MS instruments, as well as a 500-MHz NMR 
spectrometer dedicated to investigations of biofluids and other biological 
specimens. Furthermore, the contractual agreement between the TIA 
and NWU stipulates that: ‘...the Institution [NWU] agrees to have an 
open policy that encourages use of its facilities by researchers other 
than those based at the Institution…’. This policy of open access to the 
Metabolomics Platform aligns with the TIA’s objective of stimulating and 
exploiting technological innovation in order to improve economic growth 
and the quality of life of all South Africans – a view that we strongly 
share, with the hope that this review will further promote these far-
reaching ambitions.
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